Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.

Autor:	Logothetis CN; Department of Internal Medicine, University of South Florida, Tampa, FL, 33602, USA., Horvat NP; College of Medicine, University of South Florida Morsani, Tampa, FL, 33602, USA., Kurian T; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Bello C; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Chavez J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Isenalumhe L; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Shah B; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Sokol L; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Saeed H; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Pinilla J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA., Gaballa S; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Jazyk:	angličtina
Zdroj:	Oncology research [Oncol Res] 2024 May 23; Vol. 32 (6), pp. 1031-1036. Date of Electronic Publication: 2024 May 23 (Print Publication: 2024).
DOI:	10.32604/or.2024.046885
Abstrakt:	Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40-81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0-6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was 100.0% (60.0% complete response, 40.0% partial response). Medians of overall survival and progression-free survival were not reached. The estimated 2-year progression-free survival was 85.2% and overall survival was 100.0%. Four (16.6%) patients had infections related to treatment; 3 (12.0%) transformed to diffuse large B-cell lymphoma; 5 (20.8%) had a relapse or progression of EMZL; and 3 (12.0%) died unrelated to BR. BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature. Competing Interests: Research support: Ipsen, Teneobio. Consulting: AbbVie, ADC Therapeutics, AstraZeneca Beigene, Eli Lilly, Genentech, Genmab, Ipsen, and Regeneron. None of the authors have a conflict of interests for this study. (© 2024 Logothetis et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu